If GTBP advances, it will enter a fast moving area as shown on the chart between downtrend lines. Previous trend gaps and fast moving prices areas are shown in the rectangles. Will likely need a catalyst. Blue solid lines are established downtrends, green dotted lines are established uptrends. Both the uptrend and downtrend lines are established from equilibrium...
The field of immuno-oncology has seen unprecedented growth in the past 10 years, that said GT Biopharma, Inc. (NASDAQ: GTBP) could potentially catapult the advancement of the field of immuno-oncology to a new order of magnitude. GTBP’s TriKEs tech is easier to administer, store, and produce than traditional CAR-T therapy. Additionally, it demonstrates extremely...
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
Pivoting off Support and up-trending towards Resistance GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology...